12.90
-0.23%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Tianjin Lisheng Pharmaceutical Co
Its shares trade on Shenzhen under the ticker 002393.SZ. It has been listed since 23 April 2010. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.39bn and net income of CN¥418.4m. At that date it held total assets of CN¥5.58bn and shareholders' equity of CN¥4.63bn.
Tianjin Lisheng Pharmaceutical Co., Ltd. principally engages in the production and sale of chemical tablets, hard capsules, drop pills, freeze-dried powder injections, water injections, and active pharmaceutical ingredients. The company is headquartered in Tianjin, Tianjin. The company went IPO on 2010-04-23. The firm's major products are tablets, hard capsules, pills, free-dry powder injections, water injections and raw drugs, including drugs for cardio and cerebral vascular systems, anti-infection drugs and hormone drugs, among others. The company distributes its products mainly within domestic markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 23 Apr 2010
- Employees
- 1,374
- Website
- lishengpharma.com ↗
Leadership
Pay as last reported
- Mr. Ping ZhangChairman of the Board, since 2022
- Mr. Jiaying WangChief Financial Officer
- Mr. Fujun WangGeneral Manager, Director, since 2022CN¥500,000
- Ms. Xiaoyan GuoDeputy General Manager
- Mr. Changfeng LongDeputy General Manager, Chief Engineer, since 2022CN¥490,000
- Ms. Feifei MaCompany SecretaryCN¥270,000
- Mr. Bo LiuDirectorCN¥500,000
- Mr. Hao LiuDirector
- Mr. Fei TengDirector
- Ms. Qian WangDirector
- Mr. Qiang ZhouDirectorCN¥36,000
- Mr. Jiangxin FangIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Tianjin Lisheng Pharmaceutical produces cardio and cerebral vascular drugs with strong domestic market presence.
- The company employs 1,374 full-time staff, ensuring stable production capacity in Tianjin.
- Tianjin Lisheng focuses on active pharmaceutical ingredients and injectables, key segments in China's pharmaceutical sector.
Weaknesses
- Tianjin Lisheng's products are distributed mainly within domestic markets, limiting international expansion.
- The company's business is concentrated on chemical tablets and hard capsules, reducing product diversity.
- Tianjin Lisheng has no international presence, making it vulnerable to domestic market fluctuations.
Opportunities
- China's growing health care sector offers opportunities for Tianjin Lisheng to expand its product range.
- Increasing demand for anti-infection and hormone drugs in China presents growth potential.
- Tianjin Lisheng can leverage its domestic market position to enter new segments like cardiovascular drugs.
Threats
- Domestic market dependency poses a risk if China's pharmaceutical regulations change.
- Competition from other Chinese pharmaceutical firms could impact Tianjin Lisheng's market share.
- Tianjin Lisheng's reliance on domestic sales may be affected by economic downturns in China.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.